Giovanni A. Salamano M.D. ⚕️🎓
LightNews LightNews
banner
gsalamano.bsky.social
Giovanni A. Salamano M.D. ⚕️🎓
@gsalamano.bsky.social
73 followers 21 following 9 posts
It's great that you're exploring new interests and thinking about the future! At 65, you have a wealth of experience and knowledge, especially with a background as an M.D. that’s great experience 🫆
Posts Replies Media Videos
gsalamano.bsky.social
Image Challenge | The New England Journal of Medicine
The correct answer is “ The Butterfly Effect “ : an hereditary malformation probably linked to Bud Chiary Syndromic complex. As you know it’s not so simple ( ellipsis )…
www.nejm.org/image-challe...
October 3, 2025 at 9:26 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
New in the August 21/28, 2025, issue of NEJM:

Overall Survival with Nivolumab in Lung Cancer (CheckMate 816 phase 3 trial) nej.md/4k6Wlxj

Elinzanetant for Symptoms from Endocrine Therapy (OASIS-4 phase 3 trial) nej.md/3FnKwU7
Images and descriptions of what's new on NEJM.org this week
August 21, 2025 at 1:15 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Donald P. McDonnell, PhD, of @dukemedschool.bsky.social, describes the scientific foundations of a clinical trial of a first-in-class small-molecule estrogen receptor degrader to treat patients with metastatic breast cancer. Learn more: nej.md/4okw5SF
Science behind the Study Degradation of the Estrogen Receptor in Breast Cancer An illustrated diagram showing strategies to inhibit estrogen-receptor signaling in breast tumors.
August 6, 2025 at 9:40 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
A previously healthy 47-year-old woman presented to the neurology clinic with a 1-month history of worsening headaches associated with blurry vision, galactorrhea, and irregular menstrual cycles. 1/3

#MedSky #NeuroSky
Image Challenge What is the diagnosis? MRI of the head showing a mass protruding from the sella turcica into the suprasellar cistern.
August 7, 2025 at 7:06 PM
gsalamano.bsky.social
@nejm A very useful Review Article has bees published two years ago on The Journal . Also in Italy the first Lead Less Dual Chambers Electronic device has been implanted, into right ventricle and right atria. Less than AAA power supply, produced by Abbott. www.nejm.org/doi/full/10....
Cardiac Implantable Electronic Devices | NEJM
This review highlights new developments in cardiac implantable electronic devices, with an emphasis on pacemakers, newer modes of pacing, and implantable cardioverter–defibrillators.
www.nejm.org
August 1, 2025 at 1:13 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Fragile X disorders include two distinct conditions: fragile X syndrome (the most common single-gene cause of developmental delay and autism) and an entirely separate group of premutation syndromes. Learn more: nej.md/4lWrdkG

#MedSky #NeuroSky
A diagram showing CGG repeats in FMR1 expression.
July 20, 2025 at 1:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Two patients with monoclonal anti-PF4 antibodies, thrombosis, and chronic thrombocytopenia also had first-trimester pregnancy losses, findings that suggest a possible link between these antibodies and obstetrical complications. Read the full report: nej.md/4luAlx1

#MedSky #OBGYN
Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss | NEJM
Two patients with monoclonal anti-PF4 antibodies, thrombosis, and chronic thrombocytopenia also had first-trimester pregnancy losses, findings that suggest a possible link between these antibodies ...
nej.md
July 21, 2025 at 3:04 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
In the PREDMETH trial, first-line treatment of pulmonary sarcoidosis with methotrexate was noninferior to that with prednisone regarding the change at 24 weeks in the percentage of the predicted forced vital capacity. Full trial results and Research Summary: nej.md/4kdaf0o

#MedSky #PulmSky
The New England Journal of Medicine Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate A Research Summary based on Kahlmann V et al. | 10.1056/NEJMoa2501443 | Published on May 18, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
July 21, 2025 at 5:03 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Case Record of the MGH: An 86-year-old woman with a complex history that included multinodular goiter presented with neck swelling and dysphagia. A tender submandibular mass was present. A diagnosis was made. Read the full case details: nej.md/44Kya18

#MedSky
Left: An ultrasound image of the transverse right carotid artery showing a large luminal outpouching, which is most likely a pseudoaneurysm Right: An axial image from magnetic resonance angiography of the neck confirming the presence of the marked outpouching of the right common carotid artery, which is most likely a pseudoaneurysm.
July 21, 2025 at 7:46 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Once-weekly mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with #obesity or overweight. Full GLORY-1 trial results: nej.md/4koUvaP 

#MedSky #EndoSky
The New England Journal of Medicine Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight A Research Summary based on Ji L et al. | 10.1056/NEJMoa2411528 | Published on May 25, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
June 18, 2025 at 7:20 PM
gsalamano.bsky.social
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer | The relevance of fumarate DH loss of function mutation and Warburg effect on cancer cells. Leiomioma kidney cancer as example of cancer cells mutation.New England Journal of Medicine www.nejm.org/doi/full/10....
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer | NEJM
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papil...
www.nejm.org
June 18, 2025 at 11:55 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Lepodisiran is a long-acting small interfering RNA that blocks hepatic apolipoprotein(a) production. A new Quick Take video covers the ALPACA trial’s findings in patients with elevated lipoprotein(a).

🎥 Watch now: youtu.be/B0aH0O9Pk7Q

#MedSky #CardioSky
Lepodisiran: an RNA Targeting Lipoprotein(a) (ALPACA trial) | NEJM
YouTube video by NEJM Group
youtu.be
May 3, 2025 at 7:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels. Full ALPACA trial results and Research Summary: nej.md/4kWjJyn

#MedSky #CardioSky
The New England Journal of Medicine Lepodisiran — A Long-Duration siRNA Targeting Lipoprotein(a) A Research Summary based on Nissen SE et al. | 10.1056/NEJMoa2415818 | Published on March 30, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
May 4, 2025 at 7:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Food contains more than 139,000 molecules, which influence nearly half the human proteome. Systematic analysis of food–chemical interactions can potentially advance nutrition science and drug discovery. Learn more in a new Review Article: nej.md/3EEDtq4

#MedSky #EndoSky #GastroSky
Nutrition in Medicine Chemical Complexity of Food and Implications for Therapeutics An illustrated table of the overall approach to food molecule research, from Nutrition Dark Matter (NDM) to Food as Medicine.
May 7, 2025 at 10:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Nutrition in Medicine article by Giulia Menichetti, PhD, Albert-László Barabási, PhD, and Joseph Loscalzo, MD, PhD: Chemical Complexity of Food and Implications for Therapeutics nej.md/3EEDtq4

@menicgiulia.bsky.social #MedSky #EndoSky #GastroSky
Key points from the Nutrition in Medicine article "Chemical Complexity of Food and Implications for Therapeutics"
May 10, 2025 at 1:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%. Read the full review: nej.md/4mhBDvU

#MedSky #Hematology
Review Article Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress Robin Foà, M.D. Figure 1. Timeline for Studies of Frontline TKIs plus Intensive or Lower-Dose Chemotherapy in Adults with Ph-Positive ALL, 1997–2024.
May 14, 2025 at 9:25 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
An 80-year-old woman presented with a several-year history of gradual forehead enlargement and progressive hearing loss. Radiography of the skull showed marked thickening of the calvarium, with a cotton-wool appearance. Read the full case details: nej.md/3ERbNOQ

#MedSky #EndoSky #Radiology
Images in Clinical Medicine Paget’s Disease of Bone Panel A: Photo of the patient's head Panel B: Radiograph of the skull Panel C: Whole-body computed tomography Panel D: A radionucleotide bone scan
May 17, 2025 at 7:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Review Article by Robin Foà, MD: Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress nej.md/4mhBDvU

#MedSky #Hematology
Key points from the Review Article "Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress"
May 21, 2025 at 1:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
In a new editorial, Dr. Mary Frances McMullin explores the scientific foundations and clinical implications of a study on variant EPO and erythrocytosis. Read the editorial: nej.md/3YmAnNU

@qubelfastofficial.bsky.social #MedSky #Hematology
Science behind the Study Erythrocytosis and Variants of EPO An illustrated diagram of erythropoietin signaling.
April 30, 2025 at 10:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
In six families with familial polycythemia, EPO variants led to the production of a hepatic-like erythropoietin that had an altered glycosylation pattern and was more active than the renal form. Read the full study: nej.md/3Ewqt5P

#MedSky #Hematology
A figure showing isoelectric-focusing profiles of EPO isolated from patients with erythrocytosis associated with EPO variants, as compared with healthy control and recombinant EPO standard samples.
April 30, 2025 at 9:27 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky
The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.
April 30, 2025 at 9:10 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results: nej.md/4lBHwUr

#MedSky #PedSky #PulmSky
A graph showing the cumulative mean number of pulmonary exacerbations over the 52-week treatment period according to trial group.
April 25, 2025 at 4:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Adam T. Hill, MD, describes the scientific foundations of a phase 3 study of brensocatib for the treatment of bronchiectasis.

Read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: nej.md/4cANv89

#MedSky #ScienceSky
An illustrated diagram of the neutrophil — defender and offender.
April 25, 2025 at 7:17 PM
gsalamano.bsky.social
Neonatal Fc Receptor — Biology and Therapeutics | New England Journal of Medicine www.nejm.org/doi/full/10....
Neonatal Fc Receptor — Biology and Therapeutics | NEJM
FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and enhance drug delivery.
www.nejm.org
April 25, 2025 at 1:23 PM
gsalamano.bsky.social
Tumor-Infiltrating Clonal Hematopoiesis | New England Journal of Medicine www.nejm.org/doi/full/10....
Tumor-Infiltrating Clonal Hematopoiesis | NEJM
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencie...
www.nejm.org
April 25, 2025 at 1:04 PM